Mary Richardson

As Chief Scientific Officer at iuvo and one of the company’s co-founders, Mary heads up the Research and Development team. Most recently Mary served as Executive Director of Preclinical Development at Bausch + Lomb, continuing in that role when Valeant Pharmaceuticals purchased the company. Previously, she had been Director of Nonclinical Safety.

Her extensive background includes in-depth research and development experience covering the full range of the preclinical product life cycle. This includes discovery, product development, and post-market support in areas including life cycle management, geo-expansion, and manufacturing. She brings exhaustive knowledge of global regulations and standards for registration of pharmaceutical and medical device products.

Her technical leadership and expertise in drug development of small molecules, peptides, and medical devices has resulted in regulatory approval and success of numerous NDAs, INDs, IMPDs, and 510(k) submissions. She’s an in-demand speaker with many published articles in scientific journals.

Mary earned her PhD from the University of Rochester School of Medicine and Dentistry and is a highly experienced board-certified toxicologist (Diplomate of American Board of Toxicology – DABT) with broad-based technical skills in pharmaceuticals, OTC, medical devices, drug metabolism, toxicology, pharmacokinetics, and pharmacology.